In vivo fluorescence lifetime imaging for monitoring the efficacy of the cancer treatment

Clinical Cancer Research

Volumn 20, Issue 13, 2014, Pages 3531-3539

  Ardeshirpour, Yasaman ^a   Chernomordik, Victor ^a   Hassan, Moinuddin ^a,b   Zielinski, Ratal ^c,d   Capala, Jacek ^c   Gandjbakhche, Amir ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b Office of Science and Engineering Laboratories   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALVESPIMYCIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; 17-(DIMETHYLAMINOETHYLAMINO)-17-DEMETHOXYGELDANAMYCIN; AFFIBODY (ZHER2-342)2; BENZOQUINONE DERIVATIVE; HEAT SHOCK PROTEIN 90; HYBRID PROTEIN; MACROCYCLIC LACTAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG TARGETING; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR IMAGING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DIAGNOSTIC USE; DISEASE MODEL; FEMALE; FLUORESCENCE; INFRARED RADIATION; METABOLISM; TIME; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; BENZOQUINONES; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; FLUORESCENCE; HETEROGRAFTS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INFRARED RAYS; LACTAMS, MACROCYCLIC; MICE; MOLECULAR IMAGING; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; TIME FACTORS;

EID: 84903829280     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1826     Document Type: Article

References (43)

1. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004;5: 317-28.
2. Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010;28: 1138-44.
3. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23: 1147-57.
4. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG. Trastuzumab - Mechanism of action and use. New Engl J Med 2007;357: 1664.
5. Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, et al. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res 2011;17: 1561-70.
6. Allison M. The HER2 testing conundrum. Nat Biotechnol 2010;28: 117-9.
7. Joshi BP, Wang TD. Exogenous Molecular Probes for Targeted Imaging in Cancer: Focus on Multi-modal Imaging. Cancers 2010;2: 1251-87.
8. Rao J, Dragulescu-Andrasi A, Yao H. Fluorescence imaging in vivo: recent advances. Curr Opin Biotechnol 2007;18: 17-25.
9. He XX, Gao JH, Gambhir SS, Cheng Z. Near-infrared fluorescent nanoprobes for cancer molecular imaging: status and challenges. Trends Mol Med 2010;16: 574-83.
10. Hoffman RM. The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer 2005;5: 796-806.
11. Hoffman RM, Yang M. Subcellular imaging in the live mouse. Nat Protoc 2006;1: 775-82.
12. Kramer-Marek G, Capala J. Can PET Imaging Facilitate Optimization of Cancer Therapies? Curr Pharm Design 2012;18: 2657-69.
13. Nutt R, Vento LJ, Ridinger MHT. In vivo molecular imaging biomarkers: Clinical pharmacology's new "PET"? Clin Pharmacol Ther 2007;81: 792-5.
14. Bremer C, Ntziachristos V, Weissleder R. Optical-based molecular imaging: contrast agents and potential medical applications. Eur Radiol 2003;13: 231-43.
15. Ardeshirpour Y, Chernomordik V, Capala J, Hassan M, Zielinsky R, Griffiths G, et al. Using in-vivo fluorescence imaging in personalized cancer diagnostics and therapy, an image and treat paradigm. Technol Cancer Res Treat 2011;10: 549-60.
16. Corlu A, Choe R, Durduran T, Rosen MA, Schweiger M, Arridge SR, et al. Three-dimensional in vivo fluorescence diffuse optical tomography of breast cancer in humans. Opt Express 2007;15: 6696-716.
17. Keereweer S, Kerrebijn JD, van Driel PB, Xie B, Kaijzel EL, Snoeks TJ, et al. Optical image-guided surgery-where do we stand? Mol Imaging Biol 2011;13: 199-207.
18. Hellebust A, Richards-Kortum R. Advances in molecular imaging: targeted optical contrast agents for cancer diagnostics. Nanomedicine 2012;7: 429-45.
19. Lee SB, Hassan M, Fisher R, Chertov O, Chernomordik V, Kramer-Marek G, et al. Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin Cancer Res 2008;14: 3840-9.
20. Zielinski R, Hassan M, Lyakhov I, Needle D, Chernomordik V, Garcia-Glaessner A, et al. Affibody-DyLight conjugates for in vivo assessment of HER2 expression by near-infrared optical imaging. PloS ONE 2012;7: e41016.
21. Rao JH. Shedding Light on Tumors Using Nanoparticles. ACS Nano 2008;2: 1984-6.
22. Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliver Rev 2011;63: 136-51.
23. Chernomordik V, Hassan M, Lee SB, Zielinski R, Gandjbakhche A, Capala J. Quantitative analysis of Her2 receptor expression in vivo by near-infrared optical imaging. Mol Imaging 2010;9: 192-200.
24. Tichauer KM, Samkoe KS, Sexton KJ, Hextrum SK, Yang HH, Klubben WS, et al. In vivo quantification of tumor receptor binding potential with dual-reporter molecular imaging. Mol Imaging Biol 2012;14: 584-92.
25. Pogue BW, Samkoe KS, Hextrum S, O'Hara JA, Jermyn M, Srinivasan S, et al. Imaging targeted-agent binding in vivo with two probes. J Biomed Opt 2010;15: 030513.
26. Hassan M, Chernomordik V, Zielinski R, Ardeshirpour Y, Capala J, Gandjbakhche A. In vivo method to monitor changes in her2 expression using near-infrared fluorescence imaging. Mol Imaging 2012;11: 177-86.
27. Becker W. Advanced time-correlated single photon counting techniques. Berlin; New York: Springer; 2005.
28. Lakowicz JR. Principles of fluorescence spectroscopy. 2nd ed. New York: Kluwer Academic/Plenum; 1999.
29. Ardeshirpour Y, Chernomordik V, Zielinski R, Capala J, Griffiths G, Vasalatiy O, et al. In vivo fluorescence lifetime imaging monitors binding of specific probes to cancer biomarkers. PloS ONE 2012;7: e31881.
30. Berezin MY, Guo K, Akers W, Northdurft RE, Culver JP, Teng B, et al. Near-infrared fluorescence lifetime pH-sensitive probes. Biophys J 2011;100: 2063-72.
31. Alford R, Ogawa M, Hassan M, Gandjbakhche AH, Choyke PL, Kobayashi H. Fluorescence lifetime imaging of activatable target specific molecular probes. Contrast Media Mol Imaging 2010;5: 1-8.
32. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003;200: 290-7.
33. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235: 177-82.
34. Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM. Early tumor response to Hsp90 therapy using HER2 PET: Comparison with F-18-FDG PET. J Nucl Med 2006;47: 793-6.
35. Kramer-Marek G, Kiesewetter DO, Capala J. Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-Labeled affibody molecules. J Nucl Med 2009;50: 1131-9.
36. Niu G, Li ZB, Cao QZ, Chen XY. Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with Cu-64-DOTA- trastuzumab. Eur J Nucl Med Mol Imaging 2009;36: 1510-9.
37. Hoffman RM. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 1999;17: 343-59.
38. John CM, Leffler H, Kahl-Knutsson B, Svensson I, Jarvis GA. Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer. Clin Cancer Res 2003;9: 2374-83.
39. Hassan M, Riley J, Chernomordik V, Smith P, Pursley R, Lee SB, et al. Fluorescence lifetime imaging system for in vivo studies. Mol Imaging 2007;6: 229-36.
40. Sanderson S, Valenti M, Gowan S, Patterson L, Ahmad Z, Workman P, et al. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. Mol Cancer Ther 2006;5: 522-32.
41. Kaur G, Belotti D, Burger AM, Fisher-Nielson K, Borsotti P, Riccardi E, et al. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17- demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin Cancer Res 2004;10: 4813-21.
42. Citri A, Kochupurakkal BS, Yarden Y. The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 2004;3: 51-60.
43. Keren S, Gheysens O, Levin CS, Gambhir SS. A comparison between a time domain and continuous wave small animal optical imaging system. Ieee T Med Imaging 2008;27: 58-63.